AKEBIA THERAPEUTICS, INC.

Analyst Reco. Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
1.26 ^USD	-4.55%		-8.03%	+1.61%

Apr. 23	Averoa Seeks EU Approval for Chronic Kidney Disease Drug	MT
Apr. 16	Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on Akebia Therapeutics to $5 From $3.75, Maintains Buy Rating	Nov. 17	MT
HC Wainwright Upgrades Akebia Therapeutics to Buy From Neutral	23-08-28	MT
Piper Sandler Upgrades Akebia Therapeutics to Overweight From Neutral, Adjusts Price Target to $4 From $2	23-05-31	MT
HC Wainwright Adjusts Price Target on Akebia Therapeutics to $2 From $1.25, Maintains Neutral Rating	23-04-26	MT
HC Wainwright Trims Akebia Therapeutics' Price Target to $1.25 From $2, Neutral Rating Kept	22-05-16	MT
BTIG Downgrades Akebia Therapeutics to Neutral From Buy	22-03-31	MT
HC Wainwright Downgrades Akebia Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $10	22-03-31	MT
Needham Downgrades Akebia Therapeutics to Hold From Buy	22-03-31	MT
Mizuho Securities Downgrades Akebia Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $6	22-03-31	MT
Piper Sandler Downgrades Akebia Therapeutics to Neutral From Overweight, Adjusts Price Target to $2 From $8	22-03-31	MT
HC Wainwright Adjusts Akebia Therapeutics' Price Target to $10 From $6, Keeps Buy Rating	21-11-11	MT
AKEBIA THERAPEUTICS : Cantor Fitzgerald Initiates Coverage on Akebia Therapeutics With Overweight Rating, $8 Price Target	21-03-08	MT
AKEBIA THERAPEUTICS : HC Wainwright & Co. Adjusts Price Target on Akebia Therapeutics to $6 From $9, Maintains Buy Rating	21-03-08	MT
AKEBIA THERAPEUTICS : JPMorgan Downgrades Akebia Therapeutics to Underweight From Neutral	21-01-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer